Osimertinib in a patient with end-stage kidney disease not on hemodialysis

被引：0

作者：

Pirovano, Marta ^{[1
]}

Luciani, Andrea ^{[2
]}

Re Sarto, Giulia Vanessa ^{[1
]}

Bramati, Annalisa ^{[3
]}

Cosmai, Laura ^{[1
]}

机构：

[1] Fatebenefratelli Hosp, ASST Fatebenefratelli Sacco, Onconephrol Outpatient Clin, UOC Nephrol & Dialysis,Div Nephrol & Dialysis, Piazzale Principessa Clotilde 3, I-20121 Milan, Italy

[2] ASST Ovest Milanese, Osped Legnano, UOC Med Oncol, Legnano, Italy

[3] ASST Fatebenefratelli Sacco, Osped Fatebenefratelli & Oftalm, UOC Med Oncol, Milan, Italy

来源：

JOURNAL OF NEPHROLOGY | 2025年 / 38卷 / 01期

关键词：

Epidermal Growth Factor Receptor; Hemodialysis; Non-small cell lung cancer; Osimertinib;

D O I：

10.1007/s40620-024-02014-6

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) effective in non- small cell lung cancer (NSCLC) with EGFR mutations. Since the drug is primally eliminated by the fecal route no dose adjustment is needed in patient with chronic-kidney disease (CKD); despite this there is limited data about its safety in cancer patients with end-stage renal disease (ESRD). Herein, we reported a case report of a 77-year-old woman, diagnosed in 2018 with lung adenocarcinoma EGFR mutated with lymph nodal and cerebral metastasis, who started Osimertinib 80 mg/day. She under- went 41 cycles of therapy with no Osimertinib interruptions, no severe toxicities and obtaining complete radiological response. We conclude that Osimertinib has an acceptable safety profile also in cancer patients with ESRD not undergoing hemodialysis (HD).

引用

页码：275 / 278

页数：4

共 8 条

[1] Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase(R) the WHO Global Database of Individual Case Safety Reports [J].

Crosnier, Alexandre ;

Abbara, Chadi ;

Cellier, Morgane ;

Lagarce, Laurence ;

Babin, Marina ;

Bourneau-Martin, Delphine ;

Briet, Marie .

CANCERS, 2021, 13 (23)

[2] The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis [J].

Cui, Saijin ;

Zhang, Yaling ;

Liu, Lu ;

Li, Yan ;

Zhou, Rongmiao ;

Huang, Xi ;

Cao, Shiru ;

Huo, Xiangran ;

Wang, Na .

ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (02) :1851-+

[3] Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor [J].

Dickinson, Paul A. ;

Cantarini, Mireille V. ;

Collier, Jo ;

Frewer, Paul ;

Martin, Scott ;

Pickup, Kathryn ;

Ballard, Peter .

DRUG METABOLISM AND DISPOSITION, 2016, 44 (08) :1201-1212

[4] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[5] Drug-Induced Kidney Injury Caused by Osimertinib: Report of a Rare Case [J].

Niitsu, Takayuki ;

Hayashi, Terumasa ;

Uchida, Junji ;

Yanase, Takafumi ;

Tanaka, Satoshi ;

Kuroyama, Munenori ;

Ueno, Kiyonobu .

NEPHRON, 2022, 146 (01) :58-63

[6] Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies [J].

Planchard, David ;

Brown, Kathryn H. ;

Kim, Dong-Wan ;

Kim, Sang-We ;

Ohe, Yuichiro ;

Felip, Enriqueta ;

Leese, Philip ;

Cantarini, Mireille ;

Vishwanathan, Karthick ;

Jaenne, Pasi A. ;

Ranson, Malcolm ;

Dickinson, Paul A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) :767-776

[7] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [J].

Ramalingam, S. S. ;

Vansteenkiste, J. ;

Planchard, D. ;

Cho, B. C. ;

Gray, J. E. ;

Ohe, Y. ;

Zhou, C. ;

Reungwetwattana, T. ;

Cheng, Y. ;

Chewaskulyong, B. ;

Shah, R. ;

Cobo, M. ;

Lee, K. H. ;

Cheema, P. ;

Tiseo, M. ;

John, T. ;

Lin, M-C ;

Imamura, F. ;

Kurata, T. ;

Todd, A. ;

Hodge, R. ;

Saggese, M. ;

Rukazenkov, Y. ;

Soria, J-C ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) :41-50

[8] Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis [J].

Tamura, Tomohiro ;

Takagi, Yuki ;

Okubo, Hatsumi ;

Yamaguchi, Shozaburo ;

Kikkawa, Yasuko ;

Hashimoto, Ikuta ;

Kaburagi, Takayuki ;

Miura, Masatomo ;

Satoh, Hiroaki ;

Hizawa, Nobuyuki .

LUNG CANCER, 2017, 112 :225-226

← 1 →